Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (NCT05985655) | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 2023-07-06 |
Track Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.